Altogether, inhibiting proteasome activity can potentially affect the expression of unstable transcripts (e.g., PROMPTs) to regulate the expression of chromatin regulators that modulate accessibility, for example at binding sites of ER and ER cofactors (e.g., FOXA1), thus changing the biology of breast cancer. Here, ESR1 is linked to breast carcinoma.